Elanco Animal Health Incorporated [ELAN] stock Initiated by Morgan Stanley analyst, price target now $40


Elanco Animal Health Incorporated [NYSE: ELAN] price surged by 1.56 percent to reach at $0.44. The company report on November 30, 2021 that Elanco Announces Changes to Simplify Organizational Structure, Drive Profitable Growth and Focus Investments on Growth and Innovation Opportunities.

Streamlining and simplifying organizational structure to reduce complexity and focus investments in priority areas that drive growth and innovation.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Eliminating approximately 380 positions, including approximately 20% of Elanco’s senior management, creating a fourth quarter 2021 charge to GAAP net income of $65 million to $71 million and generating approximately $70 million in savings once fully realized to support delivery of the company’s adjusted gross margin and adjusted EBITDA expansion goals.

A sum of 2478880 shares traded at recent session while its average daily volume was at 3.28M shares. Elanco Animal Health Incorporated shares reached a high of $28.98 and dropped to a low of $28.13 until finishing in the latest session at $28.71.

The one-year ELAN stock forecast points to a potential upside of 19.76. The average equity rating for ELAN stock is currently 2.20, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on Elanco Animal Health Incorporated [ELAN]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ELAN shares is $35.78 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ELAN stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Morgan Stanley have made an estimate for Elanco Animal Health Incorporated shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on November 18, 2021. While these analysts kept the previous recommendation, Stifel dropped their target price from $37 to $34. The new note on the price target was released on October 28, 2021, representing the official price target for Elanco Animal Health Incorporated stock. Previously, the target price had yet another raise to $38, while Credit Suisse analysts kept a Outperform rating on ELAN stock.

The Average True Range (ATR) for Elanco Animal Health Incorporated is set at 0.86, with the Price to Sales ratio for ELAN stock in the period of the last 12 months amounting to 2.78. The Price to Book ratio for the last quarter was 1.82, with the Price to Cash per share for the same quarter was set at 0.98.

ELAN Stock Performance Analysis:

Elanco Animal Health Incorporated [ELAN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.31. With this latest performance, ELAN shares dropped by -0.10% in over the last four-week period, additionally sinking by -17.97% over the last 6 months – not to mention a drop of -4.68% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ELAN stock in for the last two-week period is set at 45.19, with the RSI for the last a single of trading hit 48.74, and the three-weeks RSI is set at 43.52 for Elanco Animal Health Incorporated [ELAN]. The present Moving Average for the last 50 days of trading for this stock 30.80, while it was recorded at 28.74 for the last single week of trading, and 32.41 for the last 200 days.

Insight into Elanco Animal Health Incorporated Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Elanco Animal Health Incorporated [ELAN] shares currently have an operating margin of -2.35 and a Gross Margin at +38.09. Elanco Animal Health Incorporated’s Net Margin is presently recorded at -17.11.

Return on Total Capital for ELAN is now -0.67, given the latest momentum, and Return on Invested Capital for the company is -5.06. Return on Equity for this stock declined to -7.99, with Return on Assets sitting at -4.20. When it comes to the capital structure of this company, Elanco Animal Health Incorporated [ELAN] has a Total Debt to Total Equity ratio set at 74.51. Additionally, ELAN Total Debt to Total Capital is recorded at 42.70, with Total Debt to Total Assets ending up at 35.69. Long-Term Debt to Equity for the company is recorded at 67.53, with the Long-Term Debt to Total Capital now at 38.70.

Reflecting on the efficiency of the workforce at the company, Elanco Animal Health Incorporated [ELAN] managed to generate an average of -$59,585 per employee. Receivables Turnover for the company is 3.33 with a Total Asset Turnover recorded at a value of 0.25.Elanco Animal Health Incorporated’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.30 and a Current Ratio set at 2.30.


The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ELAN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Elanco Animal Health Incorporated go to 11.00%.

>> 7 Top Picks for the Post-Pandemic Economy <<

Elanco Animal Health Incorporated [ELAN] Insider Position Details

There are presently around $13,743 million, in the hands of institutional investors. The top three institutional holders of ELAN stocks are: PRICE T ROWE ASSOCIATES INC /MD/ with ownership of 46,967,843, which is approximately 0.402% of the company’s market cap and around 0.30% of the total institutional ownership; VANGUARD GROUP INC, holding 40,860,388 shares of the stock with an approximate value of $1.16 billion in ELAN stocks shares; and PRIMECAP MANAGEMENT CO/CA/, currently with $869.39 million in ELAN stock with ownership of nearly -0.379% of the company’s market capitalization.

Positions in Elanco Animal Health Incorporated stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 227 institutional holders increased their position in Elanco Animal Health Incorporated [NYSE:ELAN] by around 51,121,081 shares. Additionally, 211 investors decreased positions by around 43,417,753 shares, while 88 investors held positions by with 391,580,876 shares. The mentioned changes placed institutional holdings at 486,119,710 shares, according to the latest SEC report filing. ELAN stock had 53 new institutional investments in for a total of 13,829,620 shares, while 72 institutional investors sold positions of 7,658,219 shares during the same period.